Merus (NASDAQ:MRUS) and Endonovo Therapeutics (OTCMKTS:ENDV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.
This table compares Merus and Endonovo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and recommmendations for Merus and Endonovo Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Merus presently has a consensus price target of $34.00, suggesting a potential upside of 115.19%. Given Merus’ higher probable upside, research analysts plainly believe Merus is more favorable than Endonovo Therapeutics.
Risk and Volatility
Merus has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.
Valuation & Earnings
This table compares Merus and Endonovo Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Merus||$15.36 million||23.40||-$82.61 million||($4.29)||-3.68|
|Endonovo Therapeutics||N/A||N/A||-$10.81 million||N/A||N/A|
Endonovo Therapeutics has lower revenue, but higher earnings than Merus.
Insider & Institutional Ownership
53.3% of Merus shares are held by institutional investors. 12.4% of Endonovo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Endonovo Therapeutics Company Profile
Endonovo Therapeutics, Inc. develops non-invasive electrocuetical devices for regenerative medicine. It is developing Electroceutical Therapy for the treatment of pain and post-surgical edema with a concentration on cosmetic surgeries, including breast augmentation, reduction and reconstruction surgery, rhinoplasty, and liposuction procedures. The company was incorporated in 2008 and is headquartered in Woodland Hills, California.
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.